Skip to main
DCTH

Delcath Systems (DCTH) Stock Forecast & Price Target

Delcath Systems (DCTH) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Delcath Systems Inc has demonstrated significant growth potential, highlighted by a 140% increase in Hepzato procedure volume in 2025, indicating increased physician utilization and adoption of its flagship product. The company's strong financial position is evident with a year-end cash balance of $91.0 million, reflecting operational efficiency and capacity for further investment in sales expansion. Management's strategy to increase referrals and enter new markets, along with promising clinical data from ongoing trials, positions Delcath for continued success and sustained adoption of its products in the oncology space.

Bears say

Delcath Systems Inc has revised its full-year revenue expectations downward to $83M-$85M from a prior estimate of $93M-$96M, primarily due to a notable slowdown in new site activations and a significant decrease in new patient starts linked to summer seasonality and competitive clinical trials. The company faces ongoing financial challenges, including expected discounts from the Medicaid National Drug Rebate Agreement, which have further pressured average revenue per kit and contributed to a cash flow negative situation. Additionally, with a lowered sales guidance for 2025 and persistent operational hurdles, the outlook for Delcath Systems remains concerning, indicating potential difficulty in achieving forecasted revenue levels.

Delcath Systems (DCTH) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Delcath Systems and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Delcath Systems (DCTH) Forecast

Analysts have given Delcath Systems (DCTH) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Delcath Systems (DCTH) has a Strong Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Delcath Systems (DCTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.